1. Home
  2. SNGX vs BQ Comparison

SNGX vs BQ Comparison

Compare SNGX & BQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.39

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$0.81

Market Cap

6.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
BQ
Founded
1987
2008
Country
United States
China
Employees
N/A
96
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
6.1M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
SNGX
BQ
Price
$0.39
$0.81
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
245.5K
120.2K
Earning Date
05-08-2026
01-05-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
N/A
EPS
N/A
N/A
Revenue
$119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.65
52 Week High
$6.23
$72.74

Technical Indicators

Market Signals
Indicator
SNGX
BQ
Relative Strength Index (RSI) 46.90 47.34
Support Level $0.37 $0.70
Resistance Level $0.38 $0.89
Average True Range (ATR) 0.02 0.05
MACD 0.01 0.00
Stochastic Oscillator 56.05 45.54

Price Performance

Historical Comparison
SNGX
BQ

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About BQ Boqii Holding Limited representing

Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.

Share on Social Networks: